ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
INVESTORS
[더벨] 분명한 강점과 한계, 그럼에도 국산 CAR-T가 필요한 이유
2024/06/13
더벨 – 국내 최고 자본시장(Capital Markets) 미디어 (thebell.co.kr)
Prev
[머니투데이] 큐로셀 “안발셀, 킴리아 넘는 차세대 CAR-T 치료제 자신”
Next
[더벨] 데이터로 입증한 큐로셀의 ‘안발셀’ 국산약 설 자리 만들다
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
ABOUT US
SCIENCE
FACILITY
INVESTORS
Media
Notice
Public Disclosures
Stock Information
Financials
ESG
ESG Management
Archive
CONTACT
Copyright 2023. Curocell Inc. All Rights Reserved.
